Logo for Enliven Therapeutics Inc

Enliven Therapeutics Investor Relations Material

Latest events

Logo for Enliven Therapeutics Inc

Study Update

Enliven Therapeutics
Logo for Enliven Therapeutics

Q3 2024

13 Nov, 2024
Logo for Enliven Therapeutics

Q2 2024

13 Aug, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies

Latest reports from Enliven Therapeutics Inc

Access all reports
Enliven Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of small molecule kinase inhibitors for cancer treatment. The company aims to address both existing and emerging unmet needs in oncology with a precision approach designed to improve patient survival and overall well-being. Their development pipeline includes advanced candidates such as ELVN-001 and ELVN-002, which are being explored for their potential to offer enhanced selectivity, combinability, and safety in treatment protocols. The company is headquartered in Boulder, Colorado, and its shares are listed on the Nasdaq.